ACE2 and COVID-19: The ability of anti-ACE2 IgMs from patients with COVID-19 to bind C1q and induce C3 deposition on PMECs is consistent with their playing a role in inducing the complement pathway activation that is prominent in patients with severe COVID-19 (20, 21).